357 related articles for article (PubMed ID: 33692755)
41. Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
Roeb W; Higgins J; King MC
Hum Mol Genet; 2012 Jun; 21(12):2738-44. PubMed ID: 22419737
[TBL] [Abstract][Full Text] [Related]
42. Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study.
Shafiei S; Sadrolodabaei M; Aghaei A; Ayati N; Zare Namdar S; Hemati D; Zakavi SR
Int J Endocrinol Metab; 2021 Apr; 19(2):e108781. PubMed ID: 34149846
[TBL] [Abstract][Full Text] [Related]
43. Whole genome sequencing and inheritance-based variant filtering as a tool for unraveling missing heritability in pediatric cancer.
Derpoorter C; Van Paemel R; Vandemeulebroecke K; Vanhooren J; De Wilde B; Laureys G; Lammens T
Pediatr Hematol Oncol; 2023 May; 40(4):326-340. PubMed ID: 35876323
[TBL] [Abstract][Full Text] [Related]
44. Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.
Havranek O; Kleiblova P; Hojny J; Lhota F; Soucek P; Trneny M; Kleibl Z
PLoS One; 2015; 10(10):e0140819. PubMed ID: 26506619
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients.
Vargas-Parra G; Del Valle J; Rofes P; Gausachs M; Stradella A; Moreno-Cabrera JM; Velasco A; Tornero E; Menéndez M; Muñoz X; Iglesias S; López-Doriga A; Azuara D; Campos O; Cuesta R; Darder E; de Cid R; González S; Teulé A; Navarro M; Brunet J; Capellá G; Pineda M; Feliubadaló L; Lázaro C
Hum Mutat; 2020 Dec; 41(12):2128-2142. PubMed ID: 32906215
[TBL] [Abstract][Full Text] [Related]
46. Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families.
Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Martins A; Møller P; Hovig E
Fam Cancer; 2018 Jan; 17(1):141-153. PubMed ID: 28608266
[TBL] [Abstract][Full Text] [Related]
47. Whole genome sequencing and rare variant analysis in essential tremor families.
Odgerel Z; Sonti S; Hernandez N; Park J; Ottman R; Louis ED; Clark LN
PLoS One; 2019; 14(8):e0220512. PubMed ID: 31404076
[TBL] [Abstract][Full Text] [Related]
48. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Cancer Control; 2006 Apr; 13(2):106-10. PubMed ID: 16735984
[TBL] [Abstract][Full Text] [Related]
49. Thyroid Carcinomas That Occur in Familial Adenomatous Polyposis Patients Recurrently Harbor Somatic Variants in
Nieminen TT; Walker CJ; Olkinuora A; Genutis LK; O'Malley M; Wakely PE; LaGuardia L; Koskenvuo L; Arola J; Lepistö AH; Brock P; Yilmaz AS; Eisfeld AK; Church JM; Peltomäki P; de la Chapelle A
Thyroid; 2020 Mar; 30(3):380-388. PubMed ID: 32024448
[No Abstract] [Full Text] [Related]
50. Association of rare MSH6 variants with familial breast cancer.
Wasielewski M; Riaz M; Vermeulen J; van den Ouweland A; Labrijn-Marks I; Olmer R; van der Spaa L; Klijn JG; Meijers-Heijboer H; Dooijes D; Schutte M
Breast Cancer Res Treat; 2010 Sep; 123(2):315-20. PubMed ID: 19924528
[TBL] [Abstract][Full Text] [Related]
51.
Brock P; Sevigny M; Liyanarachchi S; Comiskey DF; Li W; Saarinen S; Yilmaz AS; Nieminen AI; Ringel MD; Peltomäki P; Ollila S; Nieminen TT
Thyroid; 2024 May; 34(5):575-582. PubMed ID: 38062777
[No Abstract] [Full Text] [Related]
52. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
Hińcza K; Kowalik A; Kowalska A
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
[TBL] [Abstract][Full Text] [Related]
53. A novel CHEK2 variant identified by next generation sequencing in an Indian family with hereditary breast cancer syndrome.
Bhai P; Saxena R; Kulshrestha S; Verma IC
Cancer Genet; 2019 Jun; 235-236():13-17. PubMed ID: 31296309
[TBL] [Abstract][Full Text] [Related]
54. FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.
Tomaz RA; Sousa I; Silva JG; Santos C; Teixeira MR; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2012 Dec; 77(6):926-33. PubMed ID: 22882326
[TBL] [Abstract][Full Text] [Related]
55. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
56. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.
Grünewald TG; Bernard V; Gilardi-Hebenstreit P; Raynal V; Surdez D; Aynaud MM; Mirabeau O; Cidre-Aranaz F; Tirode F; Zaidi S; Perot G; Jonker AH; Lucchesi C; Le Deley MC; Oberlin O; Marec-Bérard P; Véron AS; Reynaud S; Lapouble E; Boeva V; Rio Frio T; Alonso J; Bhatia S; Pierron G; Cancel-Tassin G; Cussenot O; Cox DG; Morton LM; Machiela MJ; Chanock SJ; Charnay P; Delattre O
Nat Genet; 2015 Sep; 47(9):1073-8. PubMed ID: 26214589
[TBL] [Abstract][Full Text] [Related]
57. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
58. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
59. Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer.
Raitila A; Georgitsi M; Bonora E; Vargiolu M; Tuppurainen K; Mäkinen MJ; Vierimaa O; Salmela PI; Launonen V; Vahteristo P; Aaltonen LA; Romeo G; Karhu A
J Endocrinol Invest; 2009 May; 32(5):426-9. PubMed ID: 19794292
[TBL] [Abstract][Full Text] [Related]
60. Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium.
Lesueur F; Stark M; Tocco T; Ayadi H; Delisle MJ; Goldgar DE; Schlumberger M; Romeo G; Canzian F
J Clin Endocrinol Metab; 1999 Jun; 84(6):2157-62. PubMed ID: 10372725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
